In this article, we discuss the 10 hot healthcare stocks to buy now. If you want to read about some more hot healthcare stocks to buy now, go directly to 5 Hot Healthcare Stocks To Buy Now.
The rise of consumer prices has often lagged behind healthcare inflation, which includes costs for doctor visits, surgeries, and prescription drugs. This trend has been especially noticeable during economic downturns, where overall inflation slows while medical prices still rise 2-3%. However, in 2022, the US saw an inflation rate not seen in decades. Even top health stocks like Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV) were affected by this. As healthcare delivery systems faced higher costs due to shortages in areas such as nursing and supplies, consumers felt the same financial pressures during the year.
The healthcare industry faces tough conditions in 2023 due to persistently high inflation and labor shortages. However, a McKinsey report predicts improvement efforts will help the industry overcome these challenges starting in 2024. Certain segments are expected to see higher growth as shifts in profit pools will be affected by several different factors.
The McKinsey report suggests that there will be ongoing growth for healthcare services and technology (HST) profit pools. 2023 is expected to bring robust growth in the sector as providers and payers increase technology adoption. The estimated CAGR for 2021 to 2026 is 10%, reaching $81 billion by 2026. This is an increase from last year’s July estimate, driven by higher demand from payers and providers seeking improved efficiency. This growth makes HST the fastest-growing sector in healthcare. The biggest boost will come from software and platforms.
The pharmacy services sector faced worker shortages and inflationary pressure in 2022. However, 2023 is expected to bring growth. The growth rate is projected to remain steady from 2021 through 2026, reaching $65 billion in profit pools by 2026 from $55 billion in 2021. This growth is mostly due to continued drug utilization and higher specialty drug prices but is partially offset by reimbursement pressure, declining profit margins, and increased specialty generic and biosimilar growth.
AI utilization in healthcare & medicine is surging in 2023. Machine learning can offer data driven CDS to healthcare professionals, leading to increased revenue prospects. AI-powered computers can analyze data at a faster pace, potentially resulting in quicker research advancements. According to Insider Intelligence, AI in healthcare is projected to grow at an annual rate of 48% between 2017 and 2023. The utilization of AI in healthcare holds great promise for enhancing patient outcomes and reducing healthcare expenses. With a growing population, the demand for health services is expected to rise.
Prnewswire.com forecasts that the global telemedicine market will reach $197.55 billion at a CAGR of 24.12% in 2023-2028. Telemedicine offers many benefits, including reducing healthcare costs, improving efficiency and profitability, and providing patients with improved access to medical services. In recent years, telemedicine has seen significant growth. It enables patients to connect with doctors from a distance, reducing the financial burden of healthcare. As a result, many healthcare providers are eager to adopt digital health technologies to take advantage of these benefits.
Total health expenditure is expected to continue on an upward trend across the globe for the next five years. This growth is closely correlated with industry revenues in the health insurance world. However, McKinsey has cautioned that macro uncertainty will persist in part because the enhanced premium subsidies created by the American Rescue Plan Act have expired, and as a result, pricing and consumer participation may face headwinds in the coming months.
Our Methodology
For this article we first used stock screeners to identify healthcare stocks that have gained at least 2% year to date in 2023 and have an average 3-month volume of more than 5 million as of January 31. From this resultant dataset we picked the stocks with highest volumes and share price gains. The list is ranked in ascending order of average 3-month share volume. We also listed the number of hedge funds in each stock so that you can identify the healthcare stocks that are favored by hedge funds.
Hot Healthcare Stocks To Buy Now
10. Invitae Corporation (NYSE:NVTA)
Number of Hedge Fund Holders: 20
YTD Perf: 26.88%
Avg Volume: 8.2M
Invitae Corporation (NYSE:NVTA) a medical genetics company, integrates genetic information into mainstream medicine to improve the healthcare of people in the United States, Canada, and internationally. On January 9, Invitae reported preliminary, unaudited financial results for the fourth quarter and full-year 2022, including revenue, cash consumption, and commercial performance metrics. The company generated approximately $516 million in revenue in 2022, which represents a year-over-year growth of approximately 12% from $460 million in 2021. The fourth quarter of 2022 showed a revenue of around $122 million, compared to $126 million in the same period of the previous year.
At the end of the third quarter of 2022, 20 hedge funds in the database of Insider Monkey held stakes worth $129.6 million in Invitae Corporation (NYSE:NVTA), compared to 21 in the preceding quarter worth $189.6 million.
Among the hedge funds being tracked by Insider Monkey, New York-based investment firm Deerfield Management is a leading shareholder in Invitae Corporation (NYSE:NVTA) with 206.9 million shares worth more than $162.2 million.
Just like Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), Invitae Corporation (NYSE:NVTA) is one of the hot healthcare stocks to buy now.
9. Geron Corporation (NASDAQ:GERN)
Number of Hedge Fund Holders: 20
YTD Perf: 36.36%
Avg Volume: 8.5M
Geron Corporation (NASDAQ:GERN) a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. On January 6, Geron Corporation declared the pricing of a larger, underwritten public offering that includes 55,876,297 shares of its common stock being sold at a public offering price of $2.45 per share and pre-funded warrants to purchase 25,000,000 shares of its common stock. The pre-funded warrants are being sold at a public offering price of $2.449 per pre-funded warrant.
At the end of the third quarter of 2022, 16 hedge funds in the database of Insider Monkey held stakes worth $138 million in Geron Corporation (NASDAQ:GERN), compared to 12 in the preceding quarter worth $98.9 million.
Among the hedge funds being tracked by Insider Monkey, Chicago-based investment firm RA Capital Management is a leading shareholder in Geron Corporation (NASDAQ:GERN) with 30 million shares worth more than $70.5 million.
8. Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Number of Hedge Fund Holders: 27
YTD Perf: 15.57%
Avg Volume: 9.99M
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a pharmaceutical company, that develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. On January 9, Teva Pharmaceutical Industries announced that it has reached a settlement agreement with 48 US states to resolve allegations that the company played a role in the opioid crisis. The agreement ends claims and lawsuits brought against the company by various state subdivisions, including cities and counties.
On October 20, 2022, Jefferies analyst Glen Santangelo assumed a Hold rating on Teva Pharmaceutical Industries Limited. (NYSE:TEVA) stock at Buy with a $10 price target.
At the end of the third quarter of 2022, 27 hedge funds in the database of Insider Monkey held stakes worth $573 million in Teva Pharmaceutical Industries Limited (NYSE:TEVA), compared to 35 in the preceding quarter worth $733.6 million.
Among the hedge funds being tracked by Insider Monkey, Boston-based investment firm Abrams Capital Management is a leading shareholder in Teva Pharmaceutical Industries Limited (NYSE:TEVA) with 23.9 million shares worth more than $192.9 million.
7. Zomedica Corp. (NYSE:ZOM)
Number of Hedge Fund Holders: 3
YTD Perf: 69.14%
Avg Volume: 10M
Zomedica Corp. (NYSE:ZOM) a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. On January 17, Zomedica Corp announced a partnership with Structured Monitoring Products, Inc. to bring the innovative VetGuardian remote vital signs monitoring system to veterinary professionals. The system operates with zero-touch technology and will be commercially available soon.
On January 6, 2023, Dawson James analyst Jason Kolbert initiated coverage of Zomedica Corp. (NYSE:ZOM) stock with a Buy rating and $6 price target, noting that in the multi-billion dollar worldwide veterinary sector, the company is establishing itself as the top provider of a wide range of goods and services.
At the end of the third quarter of 2022, 3 hedge funds in the database of Insider Monkey held stakes worth $251,000 in Aurora Cannabis Inc. (NASDAQ:ACB), compared to 5 in the previous quarter worth $705,000.
6. Aurora Cannabis Inc. (NASDAQ:ACB)
Number of Hedge Fund Holders: 9
YTD Perf: 12.72%
Avg Volume: 10.7M
Aurora Cannabis Inc. (NASDAQ:ACB) produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. On January 4, Aurora Cannabis Inc. completed the sale of its Aurora Polaris location for a total of roughly $15 million. This was previously announced as part of the company’s ongoing restructuring plan.
On January 27, 2023, Stifel analyst W. Andrew Carter maintained a Hold rating on Aurora Cannabis Inc. (NASDAQ:ACB) stock and lowered the price target to C$1.45 from C$1.75.
At the end of the third quarter of 2022, 9 hedge funds in the database of Insider Monkey held stakes worth $47.7 million in Aurora Cannabis Inc. (NASDAQ:ACB), compared to 10 in the previous quarter worth $45.7 million.
Among the hedge funds being tracked by Insider Monkey, New York-based investment firm Mudrick Capital Management is a leading shareholder in Canopy Growth Corporation (NASDAQ:CGC) with 76.1 million shares worth more than $69.8 million.
In addition to Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), Canopy Growth Corporation (NASDAQ:CGC) is one of the hot healthcare stocks to buy now.
Click to continue reading and see 5 Hot Healthcare Stocks To Buy Now.
Suggested Articles:
- 11 Best Low Risk Dividend Stocks To Invest In
- 15 Biggest Nanotechnology Companies in the World
- 11 Best Pet Stocks To Buy
Disclosure. None. 10 Hot Healthcare Stocks To Buy Now is originally published on Insider Monkey.
Hedge Fund Resource Center